Narrative review / 2022
Prompt recognition and treatment of acquired megaloblastic anemia are critical to prevent irreversible neurologic damage from vitamin B12 deficiency.
This review provides an overview of acquired megaloblastic anemia (MA), focusing on vitamin B12 and folate requirements, biochemical pathways, laboratory testing, and classic blood and bone marrow features. Acquired MA has a broad spectrum of signs and symptoms, and delayed diagnosis of vitamin B12 deficiency can cause significant neurologic sequelae that may not fully resolve with treatment. MA is highly responsive to treatment with rapid patient improvement, but features such as pancytopenia, normal MCV, and partial treatment can complicate diagnosis and mimic other hematologic disorders.
- Study type
- Narrative review
- Who was studied
- Patients with acquired megaloblastic anemia
- What was measured
- Investigation, blood and bone marrow features, and diagnostic strategies for megaloblastic anemia
THE PAPER
How I investigate acquired megaloblastic anemia.
Torrez M, Chabot-Richards D, Babu D, Lockhart E, Foucar K. Int J Lab Hematol, 2022.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.